May 10, 2010 - LifeVest, Advanced Resuscitation Technology Showcased at Heart Rhythm 2010

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

LIFEVEST WEARABLE DEFIBRILLATOR AND ADVANCED RESUSCITATION TECHNOLOGY FROM ZOLL TO BE SHOWCASED AT HEART RHYTHM 2010   

LifeVest to be Discussed in Four Abstracts at Scientific Sessions

May 10, 2010CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that it will display its portfolio of clinical resuscitation products—including the LifeVest® Wearable Defibrillator—in Booth #331 at Heart Rhythm 2010, May 12-15 at the Colorado Convention Center in Denver. The LifeVest will be discussed during four scientific presentations during the 31st Annual Scientific Sessions.

These LifeVest presentations include:

  • Edwin Zishiri, M.D., Cleveland Clinic, will present “Appropriateness of ICD Indications: Insights from an Analysis of Mortality Rates in Patients Using a Wearable Cardioverter Defibrillator,” Wed., May 12, 5:45 p.m., Lower D Lobby.
  • John G. Chenarides, M.D., Allegheny General Hospital, will present “Wearable Defibrillator Use Prior to ICD Implantation or Evaluation,” Fri., May 14, 1:30 p.m., Room 402.
  • Nicole Bianco, Ph.D., ZOLL, will present “Impact of Transthoracic Impedance on Wearable Cardioverter Defibrillator Effectiveness,” Fri., May 14, 5:00 p.m., Exhibit Hall Posters.
  • Roger G. Carrillo, M.D., University of Miami, will present “Wearable Defibrillator Use After ICD Explantation,” Sat., May 15, 9:00 a.m., Exhibit Hall Posters.

A Rhythm Theater event focused on the LifeVest entitled “The Role of the LifeVest Wearable Defibrillator in the Continuum of Care for Patients at Risk of Sudden Cardiac Arrest,” will be presented by Joshua Cooper, M.D., University of Pennsylvania, and Ranjit Suri, M.D., Lenox Hill Heart and Vascular Institute, Thurs, May 13, 9:30 a.m., Booth 227. 

Two presentations relating to ZOLL’s resuscitation technology include:

  • Yongqin Li, Ph.D. and Wanchun Tang, M.D., Weil Institute of Critical Care Medicine, and Gary Freeman, MSEE, and Weilun Quan, Ph.D. ,ZOLL, will present “Defibrillation Current Not Energy Determines the Shock Success, ” Wed., May 12, 5:45 p.m., Lower D Lobby.
  • They will also present “Synchronized Shock in Recoil Phase of Compressed Chest Improves Shock Success,” Thurs., May 13, 9:00 a.m., Lower D Lobby.

LifeVest Provides Protection for Patients at Risk of SCA 

The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established.  The LifeVest allows a patient’s physician time to assess his/her long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA.  The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

Additional products on display from ZOLL include: 

  • The AutoPulse® Non-invasive Cardiac Support Pump, which provides automated CPR chest compressions when the heart is no longer effectively circulating blood due to ventricular fibrillation or cardiac standstill. It features an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during SCA. The AutoPulse may offer a significant advantage over manual CPR, moving blood more consistently than human providers. The device delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion.  Additionally, it offers the benefit of freeing up clinicians to focus on other life-saving interventions.
  • The R Series® Code-Ready® defibrillators are designed to extend simple, smart and ready defibrillation to every hospital department through advanced, cost-effective solutions for resuscitation.  The original R Series ALS, and the newer R Series Plus, which also has both AED and ALS capabilities at the touch of a button, offer See-Thru CPR®, an industry-unique filtering technology that allows professional rescuers to view a patient’s underlying cardiac rhythm by filtering CPR artifact during resuscitation efforts.

 About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies.  With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Copyright © 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, Code-Ready, LifeBand, LifeVest, R Series, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.